Loading…
Esperion Therapeutics, Inc. is projected to rise to $3.38 by 2027, a +6% move from its current price of $3.18. ESPR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.12 | $3.18 | $3.24 | -0.02% |
| Jul 14 | $3.09 | $3.18 | $3.27 | -0.04% |
| Jul 15 | $3.07 | $3.18 | $3.29 | -0.06% |
| Jul 16 | $3.05 | $3.18 | $3.31 | -0.09% |
| Jul 17 | $3.04 | $3.18 | $3.32 | -0.11% |
| Jul 18 | $3.03 | $3.18 | $3.33 | -0.13% |
| Jul 19 | $3.01 | $3.18 | $3.35 | -0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.01 | $3.18 | $3.35 | -0.15% |
| Week 2 | $2.94 | $3.17 | $3.41 | -0.30% |
| Week 3 | $2.89 | $3.17 | $3.47 | -0.45% |
| Week 4 | $2.85 | $3.16 | $3.51 | -0.60% |
| Week 5 | $2.81 | $3.16 | $3.55 | -0.75% |
| Week 6 | $2.77 | $3.15 | $3.58 | -0.90% |
| Week 7 | $2.74 | $3.15 | $3.62 | -1.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines to treat elevated LDL cholesterol in the United States. Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C.
Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. Esperion maintains license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH.
The company was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. It was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc. (ESPR) operates in the Healthcare sector as a biopharmaceutical company focused on LDL-C-lowering therapies in the United States. The stock is currently priced at $3.15 per share with a market capitalization of $811.73M, ranking 2693 by market cap.
Forecasts show a path of gradual price growth over the coming years. The 2026 avg price is $3.15, with a min of $1.91 and a max of $3.86, and sentiment NEUTRAL. The forecast progresses with 2027 avg $3.35 (max $4.31), 2028 avg $3.67 (max $4.85), and 2029 avg $4.03 (max $5.46) as the sentiment remains NEUTRAL or shifts to BULLISH later.
By 2030 the avg is $4.70 (max $6.48) with a BULLISH sentiment, and the path continues to 2040 avg $7.99 and 2050 avg $16.48, with progressively higher max values and bullish outlooks. These are estimates and not guarantees.
A major floor 39.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.6% away) — a key level to hold.
Price is pressing into resistance (0.3% away) — a breakout level to watch.
A major ceiling 1.5% above — clearing it would confirm fresh momentum.
Key ESPR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ESPR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.17 | Buy | $3.18 | Buy |
| MA 10 | $3.17 | Buy | $3.17 | Buy |
| MA 20 | $3.16 | Buy | $3.15 | Buy |
| MA 50 | $3.10 | Buy | $3.05 | Buy |
| MA 100 | $2.86 | Buy | $2.98 | Buy |
| MA 200 | $3.05 | Buy | $2.84 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.75 | Neutral |
| Stoch RSI (14) | 50.33 | Neutral |
| CCI (20) | 133.33 | Buy |
| Williams %R (14) | -25.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 0.63 | Buy |
| Bollinger %B (20,2) | 0.88 | Neutral |
| Stochastic %K (14) | 75.00 | Neutral |
| TRIX (15) | 0.18 | Buy |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 64.37 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 3.19 | Sell |
| ADX (14) | 34.50 | Buy |
| ATR (14) | 0.01 | Info |
The near-term technical picture is NEUTRAL. RSI14 is 70, with a SMA50 of $2.78 and a SMA200 of $3.02. Support is at $3.12 and resistance at $3.17, shaping a tight near-term range. The 30-day range spans from $2.76 to $3.60, highlighting limited volatility in the very near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.91 | $3.18 | $3.84 | 0% | Neutral | |
| $2.76 | $3.38 | $4.33 | +6% | Neutral | |
| $3.07 | $3.84 | $5.06 | +21% | Bullish | |
| $3.28 | $4.16 | $5.61 | +31% | Bullish | |
| $3.79 | $4.88 | $6.70 | +53% | Bullish | |
| $4.04 | $5.27 | $7.37 | +66% | Bullish | |
| $3.99 | $5.27 | $7.47 | +66% | Bullish | |
| $4.26 | $5.68 | $8.16 | +79% | Bullish | |
| $4.23 | $5.70 | $8.29 | +79% | Bullish | |
| $4.53 | $6.18 | $9.09 | +94% | Bullish | |
| $6.19 | $8.82 | $13.62 | +177% | Bullish | |
| $11.58 | $17.78 | $29.52 | +459% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.91 | $3.18 | $3.77 | +0.00% |
| August 2026 | $2.66 | $3.12 | $3.74 | -1.85% |
| September 2026 | $2.65 | $3.12 | $3.77 | -0.08% |
| October 2026 | $2.69 | $3.18 | $3.87 | +2.05% |
| November 2026 | $2.66 | $3.16 | $3.86 | -0.77% |
| December 2026 | $2.62 | $3.12 | $3.84 | -1.24% |
Click any year to see its month-by-month ESPR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ESPR price prediction for 2026 points to an average of $3.18 (low $1.91, high $3.84) — a potential gain of 0% on today's $3.18. A consolidation phase looks the most probable path here.
In 2027, ESPR is projected to trade between $2.76 and $4.33, averaging $3.38 — a potential gain of +6% from today's $3.18. That is up +6% on the projected 2026 average. Price action looks broadly range-bound.
Esperion Therapeutics, Inc.'s 2028 outlook centres on $3.84, within a $3.07 to $5.06 range. That is up +14% on the projected 2027 average. That marks a +21% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ESPR could reach as high as $5.61, with a base case around $4.16 and support toward $3.28 — roughly +31% from $3.18. Momentum favours further upside here.
Expect ESPR to range from $3.79 to $6.70 through 2030. The $4.88 average target implies a +53% move from current prices. That is up +17% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ESPR price prediction for 2031 points to an average of $5.27 (low $4.04, high $7.37) — a potential gain of +66% on today's $3.18. Momentum favours further upside here.
In 2032, ESPR is projected to trade between $3.99 and $7.47, averaging $5.27 — a potential gain of +66% from today's $3.18. That is 0% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Esperion Therapeutics, Inc.'s 2033 outlook centres on $5.68, within a $4.26 to $8.16 range. That is up +8% on the projected 2032 average. That marks a +79% change versus current levels. Momentum favours further upside here.
By 2034, ESPR could reach as high as $8.29, with a base case around $5.70 and support toward $4.23 — roughly +79% from $3.18. Buyers look set to stay in control over this stretch.
Expect ESPR to range from $4.53 to $9.09 through 2035. The $6.18 average target implies a +94% move from current prices. That is up +8% on the projected 2034 average. Momentum favours further upside here.
The ESPR price prediction for 2040 points to an average of $8.82 (low $6.19, high $13.62) — a potential gain of +177% on today's $3.18. Buyers look set to stay in control over this stretch.
In 2050, ESPR is projected to trade between $11.58 and $29.52, averaging $17.78 — a potential gain of +459% from today's $3.18. That is up +102% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ESPR today (≈ 314.465409 ESPR) could be worth
$5,590.89
+$4,590.89 (+459%) by 2050 · US Dollar
Based on the average projected ESPR price of $17.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ESPRwould be worth at today's price.
$1,000 invested in ESPR on Jul 10, 2025 (≈ 806.451607 ESPR) would be worth
$2,564.52
+$1,564.52 (+156.5%) today · 2.56× · US Dollar
Based on a ESPR entry price of $1.24 vs. today's $3.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.16 | $1,006.33 | +0.6% |
| 1 month ago | $3.14 | $1,012.74 | +1.3% |
| 3 months ago | $2.17 | $1,465.44 | +46.5% |
| 6 months ago | $3.55 | $895.77 | -10.4% |
| 1 year ago | $1.24 | $2,564.52 | +156.5% |
| All time (5.0y) ago | $18.32 | $173.58 | -82.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ESPR forecast.
Our base-case forecast reaches $6.40 around 2040.
Implied market cap at $6.40: $1.65B
The multi-year forecast shows a gradual rise in the average price from $3.15 in 2026 to $3.67 in 2028, with 2027 average at $3.35 and 2028 at $3.67. The implied returns move from ROI 0 in 2026 to ROI 16.4 in 2028 as sentiment remains NEUTRAL to BULLISH. From 2029 onward, the path strengthens: 2029 avg $4.03 (ROI 28), 2030 avg $4.70 (ROI 49.1), 2031 avg $4.99 (ROI 58.5), 2032 avg $5.03 (ROI 59.6).
Further into 2033-2035, the forecast shows 2033 avg $5.36 (ROI 70), 2034 avg $5.30 (ROI 68.2), and 2035 avg $5.85 (ROI 85.6). By 2040 the average price is $7.99 (ROI 153.6) and by 2050 it reaches $16.48 (ROI 423.2), with sentiment remaining BULLISH through the horizon. These are estimates, not guarantees.
The figures reflect market expectations and are subject to change based on a range of factors that can affect biotech equities.
Tap a question to reveal the answer.
2030 forecast: avg price $4.70, min $3.63, max $6.48; ROI 49.1; sentiment BULLISH.
The forecast shows a bullish sentiment from 2029 onward, with 2029 avg $4.03 and 2030 avg $4.70. The 2050 max is $27.55 and ROI reaches 423.2, though these are estimates and not guarantees.
Yes—the forecast shows a 2040 max of $12.41 and a 2050 max of $27.55, so a $10 level is within the projected range.
Current price is $3.15.
30-day range: low $2.76, high $3.60.
Esperion Therapeutics, Inc. Community Discussion
0Share your Esperion Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.